IGC Pharma Announces Interim Phase 2 Data Showing IGC-AD1 Achieved Secondary Endpoint And Demonstrated A Clinical Reduction In Alzheimer's Agitation At Week Two
IGC Pharma Announces Interim Phase 2 Data Showing IGC-AD1 Achieved Secondary Endpoint And Demonstrated A Clinical Reduction In Alzheimer's Agitation At Week Two
IGC Pharma 公佈第 2 階段中期數據，顯示 IGC-AD1 已達到次要終點，並在第二週臨床上顯示阿爾茨海默氏症的激動情緒有所減輕
IGC Pharma Announces Interim Phase 2 Data Showing IGC-AD1 Achieved Secondary Endpoint And Demonstrated A Clinical Reduction In Alzheimer's Agitation At Week Two
IGC Pharma 公佈第 2 階段中期數據，顯示 IGC-AD1 已達到次要終點，並在第二週臨床上顯示阿爾茨海默氏症的激動情緒有所減輕
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。